Neil here.
Yesterday, two of the most prominent names on the cannabis block announced one of the largest acquisitions the industry has ever seen.
In a mammoth $7.2 billion deal, Jazz Pharmaceuticals agreed to buy GW Pharmaceuticals, the company behind the very first medicinal cannabinoid product to gain FDA approval in the United States.
The deal, which is likely to close in Q2 2021, will make the combined companies a dominant force in the medical marijuana space.
The Jazz and GW acquisition news came less than two months after another cannabis merger announcement by Canadian companies Tilray and Aphria. This $4 billion deal will create the world’s largest cannabis company once the two entities combine.
If these megadeals are any indication, 2021 is about to be another blowout year for the cannabis space. They validate just how massive the industry is and give it the momentum it needs to keep growing even faster than it already has.
(In just 2020, for example, the country saw over $7 billion in medical marijuana sales alone, with over 4.3 million patients approved to use medical marijuana products.)
This is the type of momentum that companies in the cannabis startup space can use to get their feet off the ground, too. We’ve already featured a couple of them over at Angels and Entrepreneurs, including one cannabis software company that’s helping sellers deliver their products more efficiently across the United States and Canada.
If you’ve been following along over the last few months, you’ll know I’ve had my eye on this space for a while now. I truly believe that this year will bring us some of the best cannabis startups the world has ever seen.
Right now, for example, there’s one tiny company in San Diego that has discovered a massive breakthrough in the medical cannabis space. Each one of their plants is worth $1.1 million, and they could be the answer to helping people who suffer from conditions ranging from arthritis and insomnia, all the way to Crohn’s disease and Alzheimer’s.
Better yet, this company is well-positioned for insane growth. It’s only tiny now, but its valuation could skyrocket by 11,113% within just one year… making right now the perfect time to learn how to get in on the ground floor.
(Just click here to get all the details today.)
That type of growth in such a short period of time is almost unheard of for a startup company in any space. It normally takes years for any startup company to reach that kind of value. After investing, angel investors are normally in it for a long haul of about three to 10 years.
But 2021 is the perfect year for a company like this one to take a stab at that kind of rapid, sky-high growth. Here’s why…
To start, marijuana policy could be well on its way to changing very soon. This week, Majority Leader Chuck Schumer announced that marijuana reform legislation would be a top priority in the current Congress under President Joe Biden.
Schumer, alongside two other Democratic senators, pledged to prepare a draft of this legislation within the coming weeks. This is the first time U.S. lawmakers have formally made this type of marijuana reform commitment.
Both Schumer’s announcement and the GW acquisition news caused cannabis stocks to rally early in the week, with GW jumping 44.5%, Tilray adding 12%, and Aphria climbing 12.6%.
Investors across the board have high hopes that the Biden administration will loosen the country’s marijuana regulations and create even more buying opportunities in the months and years to come.
Based on the momentum the industry has already seen, I have no trouble believing that we’re about to see some of the biggest and most lucrative cannabis opportunities come out of the woodwork in both the public and private worlds.
I’ve already clued you in on one of them above, so click here to catch all the details. In the meantime, I’ll have my ear to the ground for any others that we’re bound to see over the next year and beyond.
I’ll be back soon with another update.
Until next time,
Neil Patel
Yesterday, two of the most prominent names on the cannabis block announced one of the largest acquisitions the industry has ever seen.
In a mammoth $7.2 billion deal, Jazz Pharmaceuticals agreed to buy GW Pharmaceuticals, the company behind the very first medicinal cannabinoid product to gain FDA approval in the United States.
The deal, which is likely to close in Q2 2021, will make the combined companies a dominant force in the medical marijuana space.
The Jazz and GW acquisition news came less than two months after another cannabis merger announcement by Canadian companies Tilray and Aphria. This $4 billion deal will create the world’s largest cannabis company once the two entities combine.
If these megadeals are any indication, 2021 is about to be another blowout year for the cannabis space. They validate just how massive the industry is and give it the momentum it needs to keep growing even faster than it already has.
(In just 2020, for example, the country saw over $7 billion in medical marijuana sales alone, with over 4.3 million patients approved to use medical marijuana products.)
This is the type of momentum that companies in the cannabis startup space can use to get their feet off the ground, too. We’ve already featured a couple of them over at Angels and Entrepreneurs, including one cannabis software company that’s helping sellers deliver their products more efficiently across the United States and Canada.
If you’ve been following along over the last few months, you’ll know I’ve had my eye on this space for a while now. I truly believe that this year will bring us some of the best cannabis startups the world has ever seen.
Right now, for example, there’s one tiny company in San Diego that has discovered a massive breakthrough in the medical cannabis space. Each one of their plants is worth $1.1 million, and they could be the answer to helping people who suffer from conditions ranging from arthritis and insomnia, all the way to Crohn’s disease and Alzheimer’s.
Better yet, this company is well-positioned for insane growth. It’s only tiny now, but its valuation could skyrocket by 11,113% within just one year… making right now the perfect time to learn how to get in on the ground floor.
(Just click here to get all the details today.)
That type of growth in such a short period of time is almost unheard of for a startup company in any space. It normally takes years for any startup company to reach that kind of value. After investing, angel investors are normally in it for a long haul of about three to 10 years.
But 2021 is the perfect year for a company like this one to take a stab at that kind of rapid, sky-high growth. Here’s why…
To start, marijuana policy could be well on its way to changing very soon. This week, Majority Leader Chuck Schumer announced that marijuana reform legislation would be a top priority in the current Congress under President Joe Biden.
Schumer, alongside two other Democratic senators, pledged to prepare a draft of this legislation within the coming weeks. This is the first time U.S. lawmakers have formally made this type of marijuana reform commitment.
Both Schumer’s announcement and the GW acquisition news caused cannabis stocks to rally early in the week, with GW jumping 44.5%, Tilray adding 12%, and Aphria climbing 12.6%.
Investors across the board have high hopes that the Biden administration will loosen the country’s marijuana regulations and create even more buying opportunities in the months and years to come.
Based on the momentum the industry has already seen, I have no trouble believing that we’re about to see some of the biggest and most lucrative cannabis opportunities come out of the woodwork in both the public and private worlds.
I’ve already clued you in on one of them above, so click here to catch all the details. In the meantime, I’ll have my ear to the ground for any others that we’re bound to see over the next year and beyond.
I’ll be back soon with another update.
Until next time,
Neil Patel
Follow @angelsandentrepreneurs
GW great company, held the stock for 2 years plus, got in it because I liked what the were doing and they are really unknown in the market. Well ahead of any other company in this space. Never liked the reference it being a pot stock, they are 20 plus years in developing cannabinoid based drugs. Sad to see them sell, but I will take the cash and stock in Jazz and move on.